Back to Digestive System Neuroendocrine Neoplasm

Digestive System Neuroendocrine Neoplasm — Clinical Trials

MONDO:00245032 active·2 recruitingLast updated: Mar 20, 2026, 2:46 PM

Trial Landscape

Digestive System Neuroendocrine Neoplasm has an emerging clinical trial program, driven by drug treatment and procedure.

Recruiting

Active Trials

By Approach

Drug Treatment8

Procedure5

Biological Therapy1

2 additional trials involve behavioral, dietary, diagnostic, or observational approaches.

By Phase

Phase 1

Phase 2

Phase 3

Phase 4

Sponsor Types

Academic/Other6NIH2

Trial Locations

United States8 trials

Trials often recruit across multiple countries, so totals exceed the trial count.

8 Trials

Phase 2Recruiting

NCT06202066

Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas

Sponsor:Roswell Park Cancer Institute

United StatesStarted: Apr 2026Est. completion: Oct 2028Updated: Mar 2026

Phase 4Recruiting

NCT06016855

Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors

Sponsor:Vanderbilt-Ingram Cancer Center

United StatesStarted: May 2024Est. completion: May 2028Updated: Dec 2025

Stay informed about clinical trials for Digestive System Neuroendocrine Neoplasm.

Follow this disease to get updates when trials open, close, or change status.

Follow This Disease — Free

Already have an account? Sign in to manage your watchlists.

Data sourced from ClinicalTrials.gov via Kisho's automated pipeline. Trials refreshed every 4 hours for monitored diseases.

Last sync: March 20, 2026 at 2:46 PM